Advances in pruritus mechanism and treatment of primary biliary cholangitis

WANG Haiqi; LU Xi

doi:10.7619/jcmp.20213805

Journal of Clinical Medicine in Practice > 2022 > 26(6): 128-133. > DOI: 10.7619/jcmp.20213805

WANG Haiqi, LU Xi. Advances in pruritus mechanism and treatment of primary biliary cholangitis[J]. Journal of Clinical Medicine in Practice, 2022, 26(6): 128-133. DOI: 10.7619/jcmp.20213805

Citation:

WANG Haiqi, LU Xi. Advances in pruritus mechanism and treatment of primary biliary cholangitis[J]. Journal of Clinical Medicine in Practice, 2022, 26(6): 128-133. DOI: 10.7619/jcmp.20213805

Citation:

WANG Haiqi, LU Xi. Advances in pruritus mechanism and treatment of primary biliary cholangitis[J]. Journal of Clinical Medicine in Practice, 2022, 26(6): 128-133. DOI: 10.7619/jcmp.20213805

PDF (918 KB)

Advances in pruritus mechanism and treatment of primary biliary cholangitis

WANG Haiqi¹,
LU Xi^2, ,

1.
Harbin Medical University, Harbin, Heilongjiang, 150000
2.
Department of Gastroenterology, the First Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, 150000

More Information

Received Date: September 21, 2021
Available Online: March 23, 2022
Published Date: March 27, 2022

Graphical Abstract

Abstract

Abstract

Primary biliary cholangitis (PBC) is characterized by granulomatous destruction of the interlobular bile duct, causing intrahepatic cholestasis, and eventually leading to liver fibrosis, portal hypertension, liver cirrhosis, liver failure and death. Pruritus is a prominent extrahepatic symptom in patients with PBC, and more than two-thirds of patients will develop itching in the course of the disease, seriously affecting the quality of life of patients. The molecular mechanism of PBC-related pruritus is still a hot topic at present, involving itching-causing bile acid, lysophosphatidic acid, endogenous opioid peptide, 5-hydroxytryptamine and steroid metabolites. This article reviewed the current researches on the pathogenesis and therapeutic targets of PBC-related pruritus, and discussed the evidence-based treatment recommendations and experimental treatment interventions for patients with PBC-related pruritus, so as to provide theoretical basis for the treatment of PBC-related pruritus
- primary biliary cholangitis,
- pruritus,
- cholestasis,
- bile acids,
- nuclear receptors

FullText(HTML)

References (45)

References

[1]	PRINCE M, CHETWYND A, NEWMAN W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years[J]. Gastroenterology, 2002, 123(4): 1044-1051. doi: 10.1053/gast.2002.36027
[2]	HEGADE V S, MELLS G F, FISHER H, et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the united kingdom[J]. Clin Gastroenterol Hepatol, 2019, 17(7): 1379-1387, e3. doi: 10.1016/j.cgh.2018.12.007
[3]	DONG X T, DONG X Z. Peripheral and central mechanisms of itch[J]. Neuron, 2018, 98(3): 482-494. doi: 10.1016/j.neuron.2018.03.023
[4]	JURCAKOVA D, RU F, KOLLARIK M, et al. Voltage-gated sodium channels regulating action potential generation in itch-, nociceptive-, and low-threshold mechanosensitive cutaneous C-fibers[J]. Mol Pharmacol, 2018, 94(3): 1047-1056. doi: 10.1124/mol.118.112839
[5]	MOORE C, GUPTA R, JORDT S E, et al. Regulation of pain and itch by TRP channels[J]. Neurosci Bull, 2018, 34(1): 120-142. doi: 10.1007/s12264-017-0200-8
[6]	CARRION A F, ROSEN J D, LEVY C. Understanding and treating pruritus in primary biliary cholangitis[J]. Clin Liver Dis, 2018, 22(3): 517-532. doi: 10.1016/j.cld.2018.03.005
[7]	YOSIPOVITCH G, ROSEN J D, HASHIMOTO T. Itch: From mechanism to (novel) therapeutic approaches[J]. J Allergy Clin Immunol, 2018, 142(5): 1375-1390. doi: 10.1016/j.jaci.2018.09.005
[8]	DE VLOO C, NEVENS F. Cholestatic pruritus: an update[J]. Acta Gastroenterol Belg, 2019, 82(1): 75-82.
[9]	SHAH R A, KOWDLEY K V. Mechanisms and treatments of pruritus in primary biliary cholangitis[J]. Semin Liver Dis, 2019, 39(2): 209-220. doi: 10.1055/s-0039-1679918
[10]	CIPRIANI S, RENGA B, D'AMORE C, et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling[J]. PLoS One, 2015, 10(7): e0129866. doi: 10.1371/journal.pone.0129866
[11]	YU H S, ZHAO T J, LIU S M, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch[J]. eLife, 2019, 8: e48431. doi: 10.7554/eLife.48431
[12]	MEIXIONG J, VASAVDA C, SNYDER S H, et al. MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus[J]. PNAS, 2019, 116(21): 10525-10530. doi: 10.1073/pnas.1903316116
[13]	MEIXIONG J, VASAVDA C, GREEN D, et al. Identification of a bilirubin receptor that may mediate a component of cholestatic itch[J]. eLife, 2019, 8: e44116. doi: 10.7554/eLife.44116
[14]	FUJINO H, TANAKA M, IMAMURA M, et al. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis[J]. BMC Gastroenterol, 2019, 19(1): 169. doi: 10.1186/s12876-019-1092-z
[15]	KREMER A E, MARTENS J J W W, KULIK W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus[J]. Gastroenterology, 2010, 139(3): 1008-1018, e1. doi: 10.1053/j.gastro.2010.05.009
[16]	ROBERING J W, GEBHARDT L, WOLF K, et al. Lysophosphatidic acid activates satellite Glia cells and Schwann cells[J]. Glia, 2019, 67(5): 999-1012. doi: 10.1002/glia.23585
[17]	LI X Q, ZHU J, TAO Y, et al. Elevated endogenous opioids in obstructive jaundice: the possible skin mechanisms[J]. Med Hypotheses, 2018, 116: 119-121. doi: 10.1016/j.mehy.2018.05.013
[18]	LIU X Y, GINOSAR Y, YAZDI J, et al. Cross-talk between human spinal cord μ-opioid receptor 1Y isoform and gastrin-releasing peptide receptor mediates opioid-induced scratching behavior[J]. Anesthesiology, 2019, 131(2): 381-391. doi: 10.1097/ALN.0000000000002776
[19]	BARRY D M, MUNANAIRI A, CHEN Z F. Spinal mechanisms of itch transmission[J]. Neurosci Bull, 2018, 34(1): 156-164. doi: 10.1007/s12264-017-0125-2
[20]	DÜLL M M, WOLF K, VETTER M, et al. Endogenous opioid levels do not correlate with itch intensity and therapeutic interventions in hepatic pruritus[J]. Front Med (Lausanne), 2021, 8: 641163.
[21]	AZIMI E, REDDY V B, PEREIRA P J S, et al. Substance P activates Mas-related G protein-coupled receptors to induce itch[J]. J Allergy Clin Immunol, 2017, 140(2): 447-453, e3. doi: 10.1016/j.jaci.2016.12.980
[22]	OVADIA C, LÖVGREN-SANDBLOM A, EDWARDS L A, et al. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: case series and mechanism of action[J]. J Clin Apher, 2018, 33(6): 638-644. doi: 10.1002/jca.21654
[23]	LANGEDIJK J A G M, BEUERS U H, OUDE ELFERINK R P J. Cholestasis-associated pruritus and its pruritogens[J]. Front Med (Lausanne), 2021, 8: 639674.
[24]	MORITA T, MCCLAIN S P, BATIA L M, et al. HTR7 mediates serotonergic acute and chronic itch[J]. Neuron, 2015, 87(1): 124-138. doi: 10.1016/j.neuron.2015.05.044
[25]	ZHAO Z Q, LIU X Y, JEFFRY J, et al. Descending control of itch transmission by the serotonergic system via 5-HT1A-facilitated GRP-GRPR signaling[J]. Neuron, 2014, 84(4): 821-834. doi: 10.1016/j.neuron.2014.10.003
[26]	KREMER A E, NAMER B, BOLIER R, et al. Pathogenesis and management of pruritus in PBC and PSC[J]. Dig Dis Basel Switz, 2015, 33(Suppl 2): 164-175.
[27]	EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER ELECTRONIC ADDRESS: EASLOFFICE@EASLOFFICE EU, EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. doi: 10.1016/j.jhep.2017.03.022
[28]	KUIPER E M M, VAN ERPECUM K J, BEUERS U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial[J]. Hepatology, 2010, 52(4): 1334-1340. doi: 10.1002/hep.23821
[29]	REIG A, SESÉ P, PARÉS A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response[J]. Am J Gastroenterol, 2018, 113(1): 49-55. doi: 10.1038/ajg.2017.287
[30]	WORKING SUBGROUP (ENGLISH VERSION) FOR CLINICAL PRACTICE GUIDELINES FOR PRIMARY BILIARY CIRRHOSIS. Guidelines for the management of primary biliary cirrhosis: the Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan[J]. Hepatol Res, 2014, 44(Suppl S1): 71-90.
[31]	CORPECHOT C, CHAZOUILLÈRES O, ROUSSEAU A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378(23): 2171-2181. doi: 10.1056/NEJMoa1714519
[32]	LINDOR K D, BOWLUS C L, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2019, 69(1): 394-419.
[33]	SMUTNY T, HYRSOVA L, BRAEUNING A, et al. Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism[J]. Arch Toxicol, 2021, 95(1): 11-25. doi: 10.1007/s00204-020-02916-x
[34]	PRINCE M I, BURT A D, JONES D E J. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis[J]. Gut, 2002, 50(3): 436-439. doi: 10.1136/gut.50.3.436
[35]	THORNTON J R, LOSOWSKY M S. Opioid peptides and primary biliary cirrhosis[J]. BMJ, 1988, 297(6662): 1501-1504. doi: 10.1136/bmj.297.6662.1501
[36]	MAYO M J, HANDEM I, SALDANA S, et al. Sertraline as a first-line treatment for cholestatic pruritus[J]. Hepatology, 2007, 45(3): 666-674. doi: 10.1002/hep.21553
[37]	LECKIE P, TRITTO G, MOOKERJEE R, et al. 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus[J]. Aliment Pharmacol Ther, 2012, 35(6): 696-704. doi: 10.1111/j.1365-2036.2012.04994.x
[38]	KRAWCZYK M, LIEBE R, WASILEWICZ M, et al. Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch[J]. Liver Int, 2017, 37(5): 743-747. doi: 10.1111/liv.13281
[39]	HEGADE V S, KRAWCZYK M, KREMER A E, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study[J]. Aliment Pharmacol Ther, 2016, 43(2): 294-302. doi: 10.1111/apt.13449
[40]	HEGADE V S, PECHLIVANIS A, MCDONALD J A K, et al. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus[J]. Liver Int, 2019, 39(5): 967-975. doi: 10.1111/liv.14069
[41]	HEGADE V S, KENDRICK S F W, DOBBINS R L, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J]. Lancet, 2017, 389(10074): 1114-1123. doi: 10.1016/S0140-6736(17)30319-7
[42]	DECOCK S, ROELANDTS R, STEENBERGEN W V, et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study[J]. J Hepatol, 2012, 57(3): 637-641. doi: 10.1016/j.jhep.2012.04.023
[43]	HUSSAIN A B, SAMUEL R, HEGADE V S, et al. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy[J]. Br J Dermatol, 2019, 181(6): 1138-1145. doi: 10.1111/bjd.17933
[44]	MAIONE S, COSTA B, DI MARZO V. Endocannabinoids: a unique opportunity to develop multitarget analgesics[J]. Pain, 2013, 154(Suppl 1): S87-S93.
[45]	NEFF G W, O'BRIEN C B, REDDY K R, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease[J]. Am J Gastroenterol, 2002, 97(8): 2117-2119. doi: 10.1111/j.1572-0241.2002.05852.x

[1]	YUAN Li, XIA Rongming, GAO Yueqiao, MIAO Xiufang. Analysis of early neuropsychological development in 417 premature infants and its influencing factors[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 103-106. DOI: 10.7619/jcmp.20214875
[2]	MA Linghua, LI Jiangheng, ZHONG Liuyu, HUANG Yongquan, ZHU Maoling. Clinical characteristics of pregnant woman in advanced maternal age and effect of pregnancy tests for pregnancy risks[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 50-53. DOI: 10.7619/jcmp.20214722
[3]	LIU Yangyang, YOU Yan, QIN Aiping, MA Min. A case analysis of fetal limb-body wall syndrome[J]. Journal of Clinical Medicine in Practice, 2022, 26(4): 127-129. DOI: 10.7619/jcmp.20212343
[4]	FU Ping, WU Wencui. Value of ultrasonic measurement of fetal fetal nuchal translucency thickness in early pregnancy and its relationship with adverse pregnancy outcomes[J]. Journal of Clinical Medicine in Practice, 2021, 25(15): 93-97. DOI: 10.7619/jcmp.20211030
[5]	LUO Aihua, BAO Rong, WU Tiantian, ZHU Jianlin. Value of color Doppler flow imaging combined with fetal non-stress test in diagnosis of fetal distress[J]. Journal of Clinical Medicine in Practice, 2020, 24(20): 100-102,107. DOI: 10.7619/jcmp.202020028
[6]	YIN Xiaohui, ZHOU Weihong, SUN Zhixia, XIA Jianmei, LI Ji, WANG Hua. Effect of real-time four-dimensional color Doppler ultrasonography on diangnosis of prenatal development of fetus[J]. Journal of Clinical Medicine in Practice, 2018, (22): 74-76. DOI: 10.7619/jcmp.201822024
[7]	LI Yunduan, LIU Weiwu, XU Xiuying. Multivariate analysis of fetal growth restriction and its prevention measures[J]. Journal of Clinical Medicine in Practice, 2017, (1): 90-93. DOI: 10.7619/jcmp.201701027
[8]	TIAN Ying. Effects of different feeding methods on neonatal development and maternal rehabilitation[J]. Journal of Clinical Medicine in Practice, 2016, (4): 127-129. DOI: 10.7619/jcmp.201604039
[9]	ZHAO Chunhua, WANG Yuqi. Influence of hyperbilirubinemia on neonatal nerve behavior and intellectual development[J]. Journal of Clinical Medicine in Practice, 2016, (3): 88-90,94. DOI: 10.7619/jcmp.201603027
[10]	CAO Hongzhen, BIAN Min, LI Qin, SHEN Jianqiu. Value of color Dopper ultrasonic examination in monitoring fetal renal artery blood flow parameters of patients with pregnancy-inducedhypertension syndrome and fetal growth restriction[J]. Journal of Clinical Medicine in Practice, 2014, (17): 94-96. DOI: 10.7619/jcmp.201417029

Cited By

Cited by

Periodical cited type(7)

1.	张考珍，严燕艺，商明，关换琼，张爱珍. 高龄孕妇再生育出生缺陷情况及其影响因素分析. 中外医学研究. 2022(10): 139-142 .
2.	孟远霞. 责任亲情交互护理模式干预在新生儿出生缺陷产妇中的应用效果及对产妇产后生活质量的影响. 临床医学研究与实践. 2021(04): 174-176+182 .
3.	罗丽兰，吴岸晓，王丽婷. 胎儿先天性畸形的调查结果统计及危险因素分析. 中国优生与遗传杂志. 2021(01): 107-110 .
4.	李淑妮，许晨耘，伍芳芳，蔡容燕，李春蕾，韩丽珍. 海口市2016—2019年新生儿出生缺陷情况及相关影响因素分析. 实用预防医学. 2021(07): 881-884 .
5.	章历红，赵灵. 高龄孕产妇孕前及孕期检查现状及影响因素分析. 中国计划生育学杂志. 2021(08): 1563-1567 .
6.	俞鹏，邓晓龙，袁军. 2017—2020年泰州市新生儿出生缺陷发生率调查及特征观察. 中国妇幼健康研究. 2021(09): 1245-1249 .
7.	刘清玲，刘长娣，杨舒. 胎儿发生先天性畸形的数据比例及影响因素的Logistic回归分析. 中国优生与遗传杂志. 2020(08): 1017-1019 .

Other cited types(3)

Get Citation

PDF

XML

Article views (410) PDF downloads (70) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Advances in pruritus mechanism and treatment of primary biliary cholangitis